Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus

B. Tamási, V. Brodszky, M. Péntek, L. Gulácsi, K. Hajdu, M. Sárdy, A. Szegedi, Z. Bata-Csörgő, Kinyó, F. Rencz

Research output: Article

4 Citations (Scopus)

Abstract

Background: No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. Objectives: To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. Methods: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. Results: In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (rs = −0·62, P < 0·001) and the average pain intensity VAS (rs = −0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (rs = −0·40, P < 0·001). Conclusions: This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.

Original languageEnglish
JournalBritish Journal of Dermatology
DOIs
Publication statusAccepted/In press - jan. 1 2018

Fingerprint

Pemphigus
Quality of Life
Pain Measurement
Dermatology
Skin
Cost-Benefit Analysis
Comorbidity
Anxiety
Cross-Sectional Studies
Outcome Assessment (Health Care)
Depression
Pain
Health

ASJC Scopus subject areas

  • Dermatology

Cite this

Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. / Tamási, B.; Brodszky, V.; Péntek, M.; Gulácsi, L.; Hajdu, K.; Sárdy, M.; Szegedi, A.; Bata-Csörgő, Z.; Kinyó; Rencz, F.

In: British Journal of Dermatology, 01.01.2018.

Research output: Article

@article{36831f92e62a4a739da6a4b4d3b0ce5a,
title = "Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus",
abstract = "Background: No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. Objectives: To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. Methods: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. Results: In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64{\%} women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50{\%}), mobility (43{\%}) and anxiety/depression (43{\%}). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (rs = −0·62, P < 0·001) and the average pain intensity VAS (rs = −0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (rs = −0·40, P < 0·001). Conclusions: This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.",
author = "B. Tam{\'a}si and V. Brodszky and M. P{\'e}ntek and L. Gul{\'a}csi and K. Hajdu and M. S{\'a}rdy and A. Szegedi and Z. Bata-Cs{\"o}rgő and Kiny{\'o} and F. Rencz",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjd.16883",
language = "English",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus

AU - Tamási, B.

AU - Brodszky, V.

AU - Péntek, M.

AU - Gulácsi, L.

AU - Hajdu, K.

AU - Sárdy, M.

AU - Szegedi, A.

AU - Bata-Csörgő, Z.

AU - Kinyó,

AU - Rencz, F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. Objectives: To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. Methods: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. Results: In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (rs = −0·62, P < 0·001) and the average pain intensity VAS (rs = −0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (rs = −0·40, P < 0·001). Conclusions: This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.

AB - Background: No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. Objectives: To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. Methods: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. Results: In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (rs = −0·62, P < 0·001) and the average pain intensity VAS (rs = −0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (rs = −0·40, P < 0·001). Conclusions: This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.

UR - http://www.scopus.com/inward/record.url?scp=85053502129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053502129&partnerID=8YFLogxK

U2 - 10.1111/bjd.16883

DO - 10.1111/bjd.16883

M3 - Article

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

ER -